reported that the incidences of achieving MR4.5 were 38.9% (48/126) in CML‐CP and 34.2% (13/38) in CML‐AP on olverembatinib therapy at a median of 3 months [39], while in our study, 76.92% (10/13) BCR::ABL1‐positive ALL subjects achieved CMR within first 3 cycles. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.